Journey Medical FY2025 revenue $61.9M (+10% YoY); net loss narrows to $11.4M

Journey Medical Corp

Emrosi launch contributed $14.7M net revenue; ~53,000 prescriptions filled in FY2025.
Gross margin improved to 66.2% from 62.8%, driven by higher-margin Emrosi and Qbrexza.
Adjusted EBITDA positive $2.9M ($0.12 per diluted share) vs $0.8M in prior year.
SG&A rose 10% to $44.4M due to Emrosi commercialization costs.
Accutane revenue declined $6.5M amid competitive pressures.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Journey Medical Corp reported the full year ended December 31, 2025 results: revenue $61.9 million, net income Net loss was $11.4 million, or $(0.47) per share basic and diluted, EPS $(0.47) per share basic and diluted.

Period: the full year ended December 31, 2025
Revenue: $61.9 million
Net income: Net loss was $11.4 million, or $(0.47) per share basic and diluted
EPS: $(0.47) per share basic and diluted
Result: reported results

Exact text from the filing

2 tm269707d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi TM generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately

View on SEC.gov

Browse all earnings releases →

Journey Medical Corp filing history →

Source: SEC EDGAR

accession 0001104659-26-034506

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.